US28036F1057
© PR Newswire
24.12.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy
News Preview
– In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; no clinically meaningful reductions in LVEF or LVEF <50% – – On track to deliver full 12-week Part D readout in 2Q 2026 and Phase 3 start in 4Q 2026 –BOULDER, Colo., Dec. 24, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq:...
Themefolio
Profiler
Peergroup
© PR Newswire
02.12.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
News Preview
BOULDER, Colo., Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on November 28, 2025, Edgewise granted an inducement stock option to p...
Themefolio
Profiler
Peergroup
© PR Newswire
20.11.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors
News Preview
BOULDER, Colo., Nov. 20, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran Christopher Martin to its Board of Directors. Mr. Martin brings proven success across all key commercial functions...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
12.11.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
News Preview
BOULDER, Colo., Nov. 12, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on November 10, 2025, Edgewise gra...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
10.11.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers
News Preview
BOULDER, Colo., Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced the appointment of Michael Nofi, as Chief Financial Officer (CFO), ef...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
News Preview
BOULDER, Colo., Nov. 7, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will participate in the following investor conferences:...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
News Preview
– Pivotal GRAND CANYON cohort
of sevasemten in Becker expected to read out in Q4 2026; building infrastructure to support potential commercial launch
–
–
MESA open-label extension trial of sevasemten in...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
News Preview
BOULDER, Colo., Nov. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on October 31, 2025, Edgewise grant...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
News Preview
BOULDER, Colo., Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on September 30, 2025, Edgewise gra...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society
News Preview
BOULDER, Colo., Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 30th International Annual Congress of the World Muscle Society (WMS). Importantly, the presentations will include a compilation of...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
News Preview
BOULDER, Colo., Sept. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on August 29, 2025, Edgewise granted inducement stock options to pur...
Themefolio
Profiler
Peergroup
© PR Newswire
07.08.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
News Preview
– Announced positive top-line data from the open-label extension MESA trial of sevasemten in participants with Becker muscular dystrophy who previously completed ARCH and CANYON studies –
– Announced encouraging top-line data from the Phase 2 LYNX and FOX trials of sevasemten in Duchenne muscular dystrophy –
– Advanced the Phase 2 CIRRUS-HCM t...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
20.07.2025
EWTX
LISTED
NASDAQ
EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. (“Edgewise” or “the Company”) (NASDAQ: EWTX) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or f...
Themefolio
Profiler
Peergroup
© PR Newswire
26.06.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies
News Preview
– New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings –
– Ongoing pivotal trial and FDA Type C meeting provide clear path to potential sevasemten registration as the first ever therapy for Becker –
– Encouraging Phase 2 observations in Duchenne define the dose and infor...
Themefolio
Profiler
Peergroup
© PR Newswire
03.06.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference
News Preview
BOULDER, Colo., June 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Annual Goldman Sachs Global Healthcare Conference on Monday, June 9, 2025 at 3:20 pm ET. ...
Themefolio
Profiler
Peergroup
© PR Newswire
14.05.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025
News Preview
BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, at 9:00 am ET....
Themefolio
Profiler
Peergroup
© PR Newswire
08.05.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
News Preview
– Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) –
– Strengthened balance sheet with net proceeds of approximately $188 million from the April 2025 public offering; pro-forma cash balance exceeds $624 million –
– On track to report data from the Phase 2 LYNX and FOX trials of se...
Themefolio
Profiler
Peergroup
© PR Newswire
02.04.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock
News Preview
BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 9,935,419 shares of its common stock at an offering price of $20.13 per share. Edgewise anticipates gross proceeds from the offering to be approxim...
Themefolio
Profiler
Peergroup
© PR Newswire
02.04.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)
News Preview
– Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM –
– Four-week treatment with EDG-7500 demonstrated substantial improvements in measures of feel and function, reductions in key cardiac biomarkers and positive trends in measures of diastolic function –
– EDG-...
Themefolio
Profiler
Peergroup
© PR Newswire
26.03.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time
News Preview
BOULDER, Colo., March 26, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM 28-day trial in patients with obstructive or nonobstructive HC...
Themefolio
Profiler
Peergroup
© BusinessWire
11.03.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference
News Preview
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an investigational orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage, at the Muscular Dystrophy Association...
Themefolio
Profiler
Peergroup
© BusinessWire
04.03.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025
News Preview
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 pm ET.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Prese...
Themefolio
Profiler
Peergroup
© BusinessWire
03.03.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
News Preview
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2024 and recent business highlights.
“Closing out 2024 with positive Phase 2 CANYON results, completing enrollment in GRAND CANYON and advancing CIRRUS-HCM, we are well position...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development
News Preview
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced key changes to its executive team that will strengthen its leadership and sharpen the Company’s focus on late-stage clinical development. These changes include the addition of Robert Blaustein, M.D., Ph.D., joining the Company as Chief...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025
News Preview
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming priorities for 2025. Edgewise Chief Executive Officer, Kevin Koch, Ph.D., will present these updates today at the Annual J.P. Morgan Healthcare Conference.
“We were pleased with our prog...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2025
EWTX
LISTED
NASDAQ
Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
News Preview
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 1:30 pm PT (4:30 pm ET). The discussion will include updates on its cardiova...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2024
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)
News Preview
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect muscle against co...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2024
EWTX
LISTED
NASDAQ
Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research
News Preview
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided information regarding the company’s relationship with Dr. Han Phan at Rare Disease Research.
On November 27, 2024, the U.S. Food and Drug Administration (FDA) issued a warning letter to Dr. Phan based on a 2024 site inspection related...
Themefolio
Profiler
Peergroup
© BusinessWire
26.11.2024
EWTX
LISTED
NASDAQ
Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024
News Preview
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 1 pm ET.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Pres...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
News Preview
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2024 and recent business highlights.
“We continue to make strong progress on our cardiac and skeletal muscle programs,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2024
EWTX
LISTED
NASDAQ
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
News Preview
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 29th International Annual Congress of the World Muscle Society (WMS) with an industry-sponsored symposium and the presentation of seven scientific posters. These presentations will highlight the effects of sevas...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2024
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
News Preview
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive HCM. EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specificall...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2024
EWTX
LISTED
NASDAQ
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
News Preview
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive HCM on Thu...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
